Literature DB >> 16048353

The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Iain P Hargreaves1, Andrew J Duncan, Simon J R Heales, John M Land.   

Abstract

The HMG-CoA reductase inhibitors, also known as statins, have an enviable safety profile; however, myotoxicity and to a lesser extent hepatotoxicity have been noted in some patients following treatment. Statins target several tissues, depending upon their lipophilicity, where they competitively inhibit HMG-CoA reductase, the rate-limiting enzyme for mevalonic acid synthesis and subsequently cholesterol biosynthesis. HMG-CoA reductase is also the first committed rate-limiting step for the synthesis of a range of other compounds including steroid hormones and ubidecarenone (ubiquinone), otherwise known as coenzyme Q(10) (CoQ(10)). Recent interest has focused on the possible role CoQ(10) deficiency may have in the pathophysiology of the rare adverse effects of statin treatment. Currently, there is insufficient evidence from human studies to link statin therapy unequivocally to pathologically significantly decreased tissue CoQ(10) levels. Although statin treatment has been reported to lower plasma/serum CoQ(10) status, few human studies have assessed tissue CoQ(10) status. The plasma/serum CoQ(10) level is influenced by a number of physiological factors and, therefore, has limited value as a means of assessing intracellular CoQ(10) status. In those limited studies that have assessed the effect of statin treatment upon tissue CoQ(10) levels, none have shown evidence of a fall in CoQ(10) levels. This may reflect the doses of statins used, since many appear to have been used at doses below those recommended for their maximum therapeutic effects. Moreover, the poor bioavailability in those peripheral tissues tested may not reflect the effects the agents are having in liver and muscle, the tissues commonly affected in those patients who do not tolerate statins. This article reviews the biochemistry of CoQ(10), its role in cellular metabolism and the available evidence linking possible CoQ(10) deficiency to statin therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16048353     DOI: 10.2165/00002018-200528080-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  142 in total

Review 1.  Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation?

Authors:  Tina Koumis; Joseph P Nathan; Jack M Rosenberg; Lorraine A Cicero
Journal:  Am J Health Syst Pharm       Date:  2004-03-01       Impact factor: 2.637

2.  Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans.

Authors:  P J Pentikainen; M Saraheimo; J I Schwartz; R D Amin; M S Schwartz; F Brunner-Ferber; J D Rogers
Journal:  J Clin Pharmacol       Date:  1992-02       Impact factor: 3.126

3.  Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress.

Authors:  J Lagendijk; J B Ubbink; W J Vermaak
Journal:  J Lipid Res       Date:  1996-01       Impact factor: 5.922

4.  Simvastatin-induced lactic acidosis: a rare adverse reaction?

Authors:  Anil K Goli; Sujatha A Goli; Ryland P Byrd; Thomas M Roy
Journal:  Clin Pharmacol Ther       Date:  2002-10       Impact factor: 6.875

5.  Interactions between ascorbyl free radical and coenzyme Q at the plasma membrane.

Authors:  A Arroyo; F Navarro; C Gómez-Díaz; F L Crane; F J Alcaín; P Navas; J M Villalba
Journal:  J Bioenerg Biomembr       Date:  2000-04       Impact factor: 2.945

6.  Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin.

Authors:  Jari J Lilja; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-07       Impact factor: 4.335

Review 7.  Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.

Authors:  W R Garnett
Journal:  Am J Health Syst Pharm       Date:  1995-08-01       Impact factor: 2.637

8.  Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors.

Authors:  R Laaksonen; J P Ojala; M J Tikkanen; J J Himberg
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Coenzyme Q10 and coronary artery disease.

Authors:  Y Hanaki; S Sugiyama; T Ozawa; M Ohno
Journal:  Clin Investig       Date:  1993

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  15 in total

1.  Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.

Authors:  Heiner K Berthold; Ali Naini; Salvatore Di Mauro; Maarit Hallikainen; Helena Gylling; Wilhelm Krone; Ioanna Gouni-Berthold
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.

Authors:  Nassrene Y Elmadhun; Antonio D Lassaletta; Louis M Chu; Yuhong Liu; Jun Feng; Frank W Sellke
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-17       Impact factor: 5.209

3.  Coenzyme q10 therapy.

Authors:  Juan Garrido-Maraver; Mario D Cordero; Manuel Oropesa-Ávila; Alejandro Fernández Vega; Mario de la Mata; Ana Delgado Pavón; Manuel de Miguel; Carmen Pérez Calero; Marina Villanueva Paz; David Cotán; José A Sánchez-Alcázar
Journal:  Mol Syndromol       Date:  2014-07

4.  Biochemical diagnosis of coenzyme q10 deficiency.

Authors:  Delia Yubero; Raquel Montero; Rafael Artuch; John M Land; Simon J R Heales; Iain P Hargreaves
Journal:  Mol Syndromol       Date:  2014-07

5.  Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy.

Authors:  Manish Suneja; Daniel K Fox; Brian D Fink; Judy A Herlein; Christopher M Adams; William I Sivitz
Journal:  Transl Res       Date:  2015-01-28       Impact factor: 7.012

6.  A sequence symmetry analysis of the interrelationships between statins, diabetes and skin infections.

Authors:  Humphrey H T Ko; Ricky R Lareu; Brett R Dix; Jeffery D Hughes; Richard W Parsons
Journal:  Br J Clin Pharmacol       Date:  2019-10-10       Impact factor: 4.335

7.  Squalene synthase inhibition: a novel target for the management of dyslipidemia.

Authors:  Michael H Davidson
Journal:  Curr Atheroscler Rep       Date:  2007-01       Impact factor: 5.113

Review 8.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

9.  Atorvastatin increases myocardial indices of oxidative stress in a porcine model of hypercholesterolemia and chronic ischemia.

Authors:  Neel R Sodha; Munir Boodhwani; Basel Ramlawi; Richard T Clements; Shigetoshi Mieno; Jun Feng; Shu-Hua Xu; Cesario Bianchi; Frank W Sellke
Journal:  J Card Surg       Date:  2008 Jul-Aug       Impact factor: 1.620

10.  Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.

Authors:  Pazit Bar-On; Leslie Crews; Andrew O Koob; Hideya Mizuno; Anthony Adame; Brian Spencer; Eliezer Masliah
Journal:  J Neurochem       Date:  2008-01-28       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.